About this episode

Michael and Josh summarize key trials and updates from ASCO 2026 that could influence cancer treatment practices.

ASCO 2026 is done, and Michael and Josh have created a marathon episode for you all. This week we cover "Agents of the Present", where we summarise all the important trials with updates, overall survival and progression-free survival data that could influence your practice. They cover immunotherapy, lifestyle interventions, pan-PI3K inhibitors, rare cancers (such as uveal melanoma), and antibody drug conjugates, to name a few. All the cancer types are covered, including genitourinary, gynaecological cancers, breast, colorectal, lung and lifestyle interventions! Two more episodes to come! Studies Discussed in this Episode EV-302 Extended Follow-Up ROSELLA (Ovarian Cancer) RAMPART (Adjuvant RCC) VIKTORIA-1 (HR +ve Breast Cancer) OptimUM OPTIMA (Breast Cancer) Anbenitimab and Chemotherapy (HER2 +ve Breast Cancer) TALAPRO-3 (Prostate Cancer) GLP-1 in HR +ve Breast Cancer Lifestyle Interventions in HR +ve Breast Cancer For more episodes, resources and blog posts, visit www.inquisitiveonc.com Please find us on Twitter @InquisitiveOnc! If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com Art courtesy of Taryn Silver Music courtesy of AlisiaBeats…

Sponsors

Pfizer, Merck Pharmaceuticals

More episodes of Oncology for the Inquisitive Mind

• 208. ASCO 2026 - The Plenary Episode - Part 3 · July 12, 2026 · 53 min
• 207. ASCO 2026 - Agents of the Future - Part 2 · July 5, 2026 · 1h 4m
• 205. ESTRO update with A/Prof Steven David · June 14, 2026 · 23 min

Explore listener stats, chart rankings, contacts and more on the Oncology for the Inquisitive Mind podcast page.